PharmAthene Announces $5.5 Million Public Equity Offering

ANNAPOLIS, Md., March 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE
Amex: PIP), a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that certain institutional
investors have agreed to purchase approximately $5.5 million of its common
stock and warrants in a registered public offering.

Under the terms of the purchase agreements, PharmAthene will sell an aggregate
of 2,116,055 newly issued shares of its common stock at $2.60 per share and
warrants to purchase an aggregate of 696,295 shares of its common stock at an
exercise price of $3.00 per share. The warrants will be exercisable beginning
on the 6 month anniversary of the closing date of the transaction and will
expire five years from the date they become exercisable.

The financing is expected to close on or about March 26, 2009, subject to the
satisfaction of customary closing conditions. The Company intends to use the
net proceeds from the transaction for general corporate purposes, including
the satisfaction of existing obligations.

Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital
Group, Inc. (NasdaqGM: RODM), served as lead placement agent, and Caris &
Company served as co-placement agent for the offering, and WBB Securities, LLC
acted as the Company's financial advisor.

The securities described above are being offered by PharmAthene pursuant to a
registration statement previously filed and declared effective by the
Securities and Exchange Commission. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction. The securities
may be offered only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. Copies of
the final prospectus supplement may be obtained, when available, at the
Securities and Exchange Commission's website at http://www.sec.gov or from
Rodman & Renshaw, LLC, 1251 Avenue of the Americas, 20th Floor, New York, NY
10020, Telephone: 212-356-0500.

About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its
allies by developing and commercializing medical countermeasures against
biological and chemical weapons. PharmAthene's lead product development
programs include:

-- SparVax(TM) - a second generation recombinant protective antigen (rPA)
anthrax vaccine
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve
agents
-- RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including statements
preceded by, followed by, or that include the words "potential"; "believe";
"anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may";
"should"; or similar statements are forward-looking statements. PharmAthene
disclaims, however, any intent or obligation to update these forward-looking
statements. Risks and uncertainties include risks associated with the
reliability of the results of the studies relating to human safety and
possible adverse effects resulting from the administration of the Company's
product candidates, unexpected funding delays and/or reductions or elimination
of U.S. government funding for one or more of the Company's development
programs, including without limitation our bid related to SparVax(TM) under
the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen
(rPA) Vaccine for the Strategic National Stockpile the award of government
contracts to our competitors, unforeseen safety issues, challenges related to
the development, scale-up, and/or process validation of manufacturing
processes for our product candidates, unexpected determinations that these
product candidates prove not to be effective and/or capable of being marketed
as products as well as risks detailed from time to time in PharmAthene's Form
10-K and 10-Q under the caption "Risk Factors" and in its other reports filed
with the Securities and Exchange Commission. Copies of PharmAthene's public
disclosure filings are available from its investor relations department and
our website under the investor relations tab at www.PharmAthene.com.

SOURCE PharmAthene, Inc.

Stacey Jurchison of PharmAthene, Inc., +1-410-269-2610,
Stacey.Jurchison@PharmAthene.com